Placebo Effect in Levodopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis

Levodopa-induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized.

To quantify the magnitude of the placebo response in LID trials and to identify potential moderators of this effect.

We conducted a systematic review and meta-analysis of double-blind, placebo-controlled trials in patients with PD and LID. The primary outcome was the change in dyskinesia severity in the placebo arm, pooled using random-effects model.

Thirty one publications, comprising 1329 patients, were included. Data were stratified by reporting methodology: 16 studies provided primary LS mean change data, 11 provided simple change and the remaining studies contributing solely to subgroup analyses. The primary meta-analysis, revealed a statistically significant placebo response of moderate magnitude (pooled SMD = -0.48, p < 0.0001), with significant heterogeneity (I² = 47.6%). Subgroup analyses showed this corresponded to clinically measurable improvements, including a mean reduction of -6.78 points on the UDysRS and an increase of +1.27 h in "Good On Time." Meta-regression identified that a larger placebo effect was significantly associated with older patient age (p = 0.014), a higher proportion of female participants (p = 0.016), and shorter study duration (p = 0.006).

The placebo response in LID is a consistent, clinically relevant phenomenon modulated by patient demographics and trial duration. Quantifying this response is essential for design and accurate interpretation of future trials.